CME/CE Accredited Session
Sponsored by Industry
Click For Session Details
Session Times Listed in ET
Ty J. Gluckman, MD, FACC, FAHA | Charles Vega, MD, FAAFP
With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! There’s new information about vaccines daily but it can be challenging to keep up. Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss vaccines for children 5-11 years old, and vaccine-associated Myocarditis.
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR
Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine, Irvine, CA
Oscar A. de Leon-Casasola, MD | Katherine E. Galluzzi, DO, CMD, FACOFP
The most appropriate analgesic regimen for some patients may include the use of opioids as a component of pain management. Opioids may be considered for pain severe enough to require an opioid when alternative treatments are inadequate and when the benefits of opioids are expected to outweigh the risks. Before prescribing opioids, it is essential for clinicians to screen patients for risk of opioid-related aberrant behaviors using validated tools. It is also essential to differentiate among opioid tolerance, physical dependence, and addiction, and as to how these conditions may present clinically.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Professor of Anesthesiology and Medicine, Senior Vice-Chair, The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Chief, Pain Medicine and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY
Professor and Chair, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, PA
Supported by Opioid Analgesic REMS Program Companies
Lipoprotein(a) is a genetically determined LDL-C like particle that is uniquely proatherogenic, prothrombotic, and proinflammatory. While emerging therapies are on the horizon, there are no current FDA approved medicinal treatment options for Lp(a). Understanding the prevalence and need to test for Lp(a) will hopefully help your patients mitigate potential cardiovascular risks via lifestyle modification and informing clinical practice.
Sponsored by Novartis Pharmaceuticals Corporation